Shares of the company are trading at $30.97 a bit higher than $28.28, the 50 day moving average and which is just over the 200 day moving average of $28.28. The 50 day moving average moved up $2.69 and the 200 day average went up $2.69 or +9.53%. Trading was heavy with 575K shares changing hands on Tuesday. Volume was up 882.08% over the stocks average daily volume.
Investors are more bullish on Cellectis S.A. – American Depos recently as evidenced by the motion in short interest. The stock had a fall in short interest from September 15, 2017 to September 29, 2017 of -16.39%. Short shares decreased 133,394 over that timeframe. Days to cover increased from 1.0 to 7.0 and the percentage of shorted shares is 0.02% as of September 29.
These firms have modified their investment in CLLS. Vident Investment Advisory, LLC downsized its ownership by shedding 1,013 shares a decrease of 2.0%. Vident Investment Advisory, LLC controls 49,981 shares worth $1,291,000. The value of the position overall is up by 5.5%. As of the end of the quarter Venbio Select Advisor LLC had disposed of a total of 11,407 shares trimming its position 11.7%. The value of the investment in CLLS decreased from $2,330,000 to $2,212,000 a change of $118,000 quarter over quarter.
Next Financial Group, Inc reduced its position by selling 100 shares a decrease of 25.0% from 03/31/2017 to 06/30/2017. Next Financial Group, Inc claims 300 shares valued at $8,000,000. The total value of its holdings increased 79,900.0%. Cutler Group LP divested its holdings by selling 600 shares a decrease of 73.1% in the quarter. Cutler Group LP now holds 221 shares with a value of $6,000. The value of the position overall is down by 71.4%.
In the latest earnings report the EPS was $-2.30 and is projected to be $-2.39 for the current year with 35,862,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.41 and the next full year EPS is anticipated to be $-2.19.
Cellectis S.A., a gene-editing company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies which develop in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART38 for T-cell ALL and MM; and UCART22 for ALL. It has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; and The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various types of liquid tumors. Cellectis S.A. was founded in 1999 and is based in Paris, France..